European Medical Solutions (STU:AS00) Long-Term Debt: €7.05 Mil (As of Dec. 2025)


STU:AS00 European Medical Solutions STU:AS00
43 GF Score
Price €3.98
GF Value €8.16
! 2 Warning Signs
View Full Analysis

What is European Medical Solutions Long-Term Debt?

European Medical Solutions STU:AS00 -7.87% 43 Long-Term Debt is €7.05 Mil as of Dec. 2025. GuruFocus rates STU:AS00 with a GF Score™ of 43/100 and a GF Value™ of €8.16. The stock has 2 warning signs investors should review.

European Medical Solutions's Long-Term Debt for the quarter that ended in Dec. 2025 was €7.05 Mil.

European Medical Solutions's quarterly Long-Term Debt declined from Dec. 2024 (€8.99 Mil) to Jun. 2025 (€6.62 Mil) but then increased from Jun. 2025 (€6.62 Mil) to Dec. 2025 (€7.05 Mil).

European Medical Solutions's annual Long-Term Debt declined from Dec. 2023 (€9.10 Mil) to Dec. 2024 (€8.99 Mil) and declined from Dec. 2024 (€8.99 Mil) to Dec. 2025 (€7.05 Mil).

European Medical Solutions  (STU:AS00) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

European Medical Solutions Long-Term Debt Related Terms

European Medical Solutions Long-Term Debt Historical Data

* Premium members only.

The historical data trend for European Medical Solutions's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Medical Solutions Long-Term Debt Chart

European Medical Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.50 6.61 9.10 8.99 7.05

European Medical Solutions Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.10 8.03 8.99 6.62 7.05
STU:AS00
43GF Score
European Medical Solutions STU:AS00
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €7.05 Mil mean?
European Medical Solutions (STU:AS00) has a Long-Term Debt of €7.05 Mil as of Dec. 2025.
Is European Medical Solutions' Long-Term Debt too high?
European Medical Solutions' current Long-Term Debt is €7.05 Mil. Overall, European Medical Solutions has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' Long-Term Debt compare to VRTX and REGN?
European Medical Solutions' Long-Term Debt of €7.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. European Medical Solutions's current Long-Term Debt is €7.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current Long-Term Debt of €7.05 Mil. The stock's GF Value™ is €8.16, compared to a current price of €3.98 — trading 51.2% below its estimated fair value. The current Long-Term Debt is €7.05 Mil. European Medical Solutions' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current Long-Term Debt is €7.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is European Medical Solutions (STU:AS00) Overvalued in 2026?

Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued. The current stock price of €3.98 is trading 51.2% below its estimated GF Value™ of €8.16.

Key valuation signals for STU:AS00:

  • Long-Term Debt: €7.05 Mil
  • GF Value™: €8.16 vs. price of €3.98 (51.2% below fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

European Medical Solutions Business Description

Other Exchanges ALEMS:Belgium
Address 7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
43GF Score

Get the complete analysis for STU:AS00

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.98
Price
€8.16
GF Value